Clinical Trial

. 2021 Dec;22(12):1669-1680.

doi: 10.1016/S1470-2045(21)00573-8. Epub 2021 Nov 3.

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

David J Pinato¹, Josep Tabernero², Mark Bower³, Lorenza Scotti⁴, Meera Patel⁵, Emeline Colomba⁶, Saoirse Dolly⁷, Angela Loizidou⁸, John Chester⁹, Uma Mukherjee¹⁰, Alberto Zambelli¹¹, Alessia Dalla Pria³, Juan Aguilar-Company², Diego Ottaviani¹², Amani Chowdhury¹², Eve Merry¹², Ramon Salazar¹³, Alexia Bertuzzi¹⁴, Joan Brunet¹⁵, Matteo Lambertini¹⁶, Marco Tagliamento¹⁶, Anna Pous¹⁵, Ailsa Sita-Lumsden⁷, Krishnie Srikandarajah⁷, Johann Colomba⁶, Fanny Pommeret⁶, Elia Seguí¹⁷, Daniele Generali¹⁸, Salvatore Grisanti¹⁹, Paolo Pedrazzoli²⁰, Gianpiero Rizzo²¹, Michela Libertini²², Charlotte Moss²³, Joanne S Evans⁵, Beth Russell²³, Nadia Harbeck²⁴, Bruno Vincenzi²⁵, Federica Biello²⁶, Rossella Bertulli²⁷, Raquel Liñan¹⁵, Sabrina Rossi¹⁴, Maria Carmen Carmona-García¹⁵, Carlo Tondini¹¹, Laura Fox²⁸, Alice Baggi¹⁹, Vittoria Fotia¹¹, Alessandro Parisi²⁹, Giampero Porzio³⁰, Maristella Saponara³¹, Claudia Andrea Cruz¹⁷, David García-Illescas², Eudald Felip¹⁵, Ariadna Roqué Lloveras¹⁵, Rachel Sharkey³, Elisa Roldán², Roxana Reyes¹⁷, Irina Earnshaw¹², Daniela Ferrante⁴, Javier Marco-Hernández³², Isabel Ruiz-Camps³³, Gianluca Gaidano³⁴, Andrea Patriarca³⁴, Riccardo Bruna³⁴, Anna Sureda³⁵, Clara Martinez-Vila³⁶, Ana Sanchez de Torre³⁷, Luca Cantini³⁸, Marco Filetti³⁹, Lorenza Rimassa⁴⁰, Lorenzo Chiudinelli¹¹, Michela Franchi¹¹, Marco Krengli⁴¹, Armando Santoro⁴⁰, Aleix Prat⁴², Mieke Van Hemelrijck²³, Nikolaos Diamantis¹⁰, Thomas Newsom-Davis³, Alessandra Gennari²⁶, Alessio Cortellini⁴³; OnCovid study group

Collaborators, Affiliations

Collaborators

OnCovid study group:
Judith Swallow, Chris Chung, Gino Dettorre, Neha Chopra, Alvin Jx Lee, Christopher Ct Sng, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Grisma Patel, Anjui Wu, Alasdair Sinclair, Gehan Soosaipillai, Eleanor Jones, Nikolaos Diamantis, Uma Mukherjee, Amanda Jackson, Martine Piccart, Fanny Pommeret, Johann Colomba, Emeline Colomba-Blameble, Aleix Prat, Claudia A Cruz, Roxana Reyes, Elia Segui, Javier Marco-Hernández, Josep Tabernero, Juan Aguilar-Company, Isabel Ruiz-Camps, Laura Fox, David Garcia Illescas, Oriol Mirallas, Elisa Roldán, Anna Carbó, Isabel Garcia, Rachel Wuerstlein, Ricard Mesia, Clara Maluquer, Francesca D'Avanzo, Giuseppe Tonini, Salvatore Provenzano, Valeria Tovazzi, Corrado Ficorella, Paola Queirolo, Raffaele Giusti, Francesca Mazzoni, Federica Zoratto, Marco Tucci, Rossana Berardi, Annalisa Guida, Sergio Bracarda, Maria Iglesias

Affiliations

¹ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk.
² Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
³ Department of Oncology, Chelsea and Westminster Hospital, London, UK; National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
⁴ Unit of Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
⁵ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
⁶ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁷ Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁸ Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK; Medical Oncology, Velindre Cancer Centre, Cardiff, UK.
¹⁰ Medical Oncology, Barts Health NHS Trust, London, UK.
¹¹ Oncology Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
¹² Cancer Division, University College London Hospitals, London, UK.
¹³ Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program, Hospitalet de Llobregat, Barcelona, Spain.
¹⁴ Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
¹⁵ Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
¹⁶ Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy.
¹⁷ Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
¹⁸ Multidisciplinary Breast Pathology and Translational Research Unit, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
¹⁹ Medical Oncology Unit, Spedali Civili, Brescia, Italy; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
²⁰ Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
²¹ Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
²² Medical Oncology Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
²³ Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
²⁴ Department of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and Comprehensive Cancer Center Munich, University Hospital Munich, Munich, Germany.
²⁵ Policlinico Universitario Campus Bio-Medico, Rome, Italy.
²⁶ Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
²⁷ Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
²⁸ Haematology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
²⁹ Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
³⁰ Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
³¹ Melanoma and Sarcoma Medical Treatment Unit, Istituto Europeo di Oncologia, Milan, Italy.
³² Department of Internal Medicine, Hospital Clinic, Barcelona, Spain.
³³ Infectious Diseases, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
³⁴ Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
³⁵ Haematology Department, ICO L'Hospitalet, Oncobell Program, Hospitalet de Llobregat, Barcelona, Spain.
³⁶ Fundació Althaia Manresa, Manresa, Spain.
³⁷ Hospital Universitario XII de Octubre, Madrid, Spain.
³⁸ Medical Oncology, Azienda Ospedaliero Universitaria, Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
³⁹ Medical Oncology, Sant'Andrea Hospital, Rome, Italy.
⁴⁰ Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁴¹ Division of Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
⁴² Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain, Barcelona, Spain.
⁴³ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

PMID: 34741822
PMCID: PMC8565932
DOI: 10.1016/S1470-2045(21)00573-8

Clinical Trial

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

David J Pinato et al. Lancet Oncol. 2021 Dec.

. 2021 Dec;22(12):1669-1680.

doi: 10.1016/S1470-2045(21)00573-8. Epub 2021 Nov 3.

Authors

Collaborators

OnCovid study group:
Judith Swallow, Chris Chung, Gino Dettorre, Neha Chopra, Alvin Jx Lee, Christopher Ct Sng, Yien Ning Sophia Wong, Myria Galazi, Sarah Benafif, Palma Dileo, Grisma Patel, Anjui Wu, Alasdair Sinclair, Gehan Soosaipillai, Eleanor Jones, Nikolaos Diamantis, Uma Mukherjee, Amanda Jackson, Martine Piccart, Fanny Pommeret, Johann Colomba, Emeline Colomba-Blameble, Aleix Prat, Claudia A Cruz, Roxana Reyes, Elia Segui, Javier Marco-Hernández, Josep Tabernero, Juan Aguilar-Company, Isabel Ruiz-Camps, Laura Fox, David Garcia Illescas, Oriol Mirallas, Elisa Roldán, Anna Carbó, Isabel Garcia, Rachel Wuerstlein, Ricard Mesia, Clara Maluquer, Francesca D'Avanzo, Giuseppe Tonini, Salvatore Provenzano, Valeria Tovazzi, Corrado Ficorella, Paola Queirolo, Raffaele Giusti, Francesca Mazzoni, Federica Zoratto, Marco Tucci, Rossana Berardi, Annalisa Guida, Sergio Bracarda, Maria Iglesias

Affiliations

¹ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk.
² Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
³ Department of Oncology, Chelsea and Westminster Hospital, London, UK; National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
⁴ Unit of Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
⁵ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
⁶ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁷ Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁸ Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK; Medical Oncology, Velindre Cancer Centre, Cardiff, UK.
¹⁰ Medical Oncology, Barts Health NHS Trust, London, UK.
¹¹ Oncology Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
¹² Cancer Division, University College London Hospitals, London, UK.
¹³ Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program, Hospitalet de Llobregat, Barcelona, Spain.
¹⁴ Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
¹⁵ Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
¹⁶ Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy.
¹⁷ Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
¹⁸ Multidisciplinary Breast Pathology and Translational Research Unit, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
¹⁹ Medical Oncology Unit, Spedali Civili, Brescia, Italy; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
²⁰ Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
²¹ Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
²² Medical Oncology Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
²³ Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
²⁴ Department of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and Comprehensive Cancer Center Munich, University Hospital Munich, Munich, Germany.
²⁵ Policlinico Universitario Campus Bio-Medico, Rome, Italy.
²⁶ Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
²⁷ Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
²⁸ Haematology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
²⁹ Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
³⁰ Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
³¹ Melanoma and Sarcoma Medical Treatment Unit, Istituto Europeo di Oncologia, Milan, Italy.
³² Department of Internal Medicine, Hospital Clinic, Barcelona, Spain.
³³ Infectious Diseases, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
³⁴ Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
³⁵ Haematology Department, ICO L'Hospitalet, Oncobell Program, Hospitalet de Llobregat, Barcelona, Spain.
³⁶ Fundació Althaia Manresa, Manresa, Spain.
³⁷ Hospital Universitario XII de Octubre, Madrid, Spain.
³⁸ Medical Oncology, Azienda Ospedaliero Universitaria, Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
³⁹ Medical Oncology, Sant'Andrea Hospital, Rome, Italy.
⁴⁰ Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
⁴¹ Division of Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Azienda Ospedaliera Maggiore Della Caritá, Novara, Italy.
⁴² Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain, Barcelona, Spain.
⁴³ Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

PMID: 34741822
PMCID: PMC8565932
DOI: 10.1016/S1470-2045(21)00573-8

Abstract

Background: The medium-term and long-term impact of COVID-19 in patients with cancer is not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and their impact on the survival of patients with cancer. We also aimed to describe patterns of resumption and modifications of systemic anti-cancer therapy following recovery from SARS-CoV-2 infection.

Methods: OnCovid is an active European registry study enrolling consecutive patients aged 18 years or older with a history of solid or haematological malignancy and who had a diagnosis of RT-PCR confirmed SARS-CoV-2 infection. For this retrospective study, patients were enrolled from 35 institutions across Belgium, France, Germany, Italy, Spain, and the UK. Patients who were diagnosed with SARS-CoV-2 infection between Feb 27, 2020, and Feb 14, 2021, and entered into the registry at the point of data lock (March 1, 2021), were eligible for analysis. The present analysis was focused on COVID-19 survivors who underwent clinical reassessment at each participating institution. We documented prevalence of COVID-19 sequelae and described factors associated with their development and their association with post-COVID-19 survival, which was defined as the interval from post-COVID-19 reassessment to the patients' death or last follow-up. We also evaluated resumption of systemic anti-cancer therapy in patients treated within 4 weeks of COVID-19 diagnosis. The OnCovid study is registered in ClinicalTrials.gov, NCT04393974.

Findings: 2795 patients diagnosed with SARS-CoV-2 infection between Feb 27, 2020, and Feb 14, 2021, were entered into the study by the time of the data lock on March 1, 2021. After the exclusion of ineligible patients, the final study population consisted of 2634 patients. 1557 COVID-19 survivors underwent a formal clinical reassessment after a median of 22·1 months (IQR 8·4-57·8) from cancer diagnosis and 44 days (28-329) from COVID-19 diagnosis. 234 (15·0%) patients reported COVID-19 sequelae, including respiratory symptoms (116 [49·6%]) and residual fatigue (96 [41·0%]). Sequelae were more common in men (vs women; p=0·041), patients aged 65 years or older (vs other age groups; p=0·048), patients with two or more comorbidities (vs one or none; p=0·0006), and patients with a history of smoking (vs no smoking history; p=0·0004). Sequelae were associated with hospitalisation for COVID-19 (p<0·0001), complicated COVID-19 (p<0·0001), and COVID-19 therapy (p=0·0002). With a median post-COVID-19 follow-up of 128 days (95% CI 113-148), COVID-19 sequelae were associated with an increased risk of death (hazard ratio [HR] 1·80 [95% CI 1·18-2·75]) after adjusting for time to post-COVID-19 reassessment, sex, age, comorbidity burden, tumour characteristics, anticancer therapy, and COVID-19 severity. Among 466 patients on systemic anti-cancer therapy, 70 (15·0%) permanently discontinued therapy, and 178 (38·2%) resumed treatment with a dose or regimen adjustment. Permanent treatment discontinuations were independently associated with an increased risk of death (HR 3·53 [95% CI 1·45-8·59]), but dose or regimen adjustments were not (0·84 [0·35-2·02]).

Interpretation: Sequelae post-COVID-19 affect up to 15% of patients with cancer and adversely affect survival and oncological outcomes after recovery. Adjustments to systemic anti-cancer therapy can be safely pursued in treatment-eligible patients.

Funding: National Institute for Health Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DJP reports lecture fees from ViiV Healthcare, Bayer Healthcare, Bristol Myers Squibb, Roche, Eisai, and Falk Foundation; travel expenses from Bristol Myers Squibb and Bayer Healthcare; consulting fees from Mina Therapeutics, Eisai, Roche, DaVolterra, and Astra Zeneca; and research funding (to institution) from Merck Sharp and Dohme and Bristol Myers Squibb, outside of the submitted work. MLa acted as consultant for Roche, Novartis, Lilly, and AstraZeneca, outside of the submitted work, and received speaker honoraria from Roche, Novartis, Lilly, Pfizer, Takeda, and Sandoz, outside of the submitted work. EF reports research funding to institution from Pfizer, outside of the submitted work, and travel expenses from Lilly, Novartis, Pfizer, and Esai, outside of the submitted work. TN-D reports consulting fees from Amgen, Bayer, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novartis, Otsuka, Pfizer, Roche, and Takeda, outside of the submitted work; speakers fees from AstraZeneca, Merck Sharp and Dohme, Roche, and Takeda, outside of the submitted work; and travel, accommodation, and expenses from AstraZenca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp and Dohme, Otsuka, Roche, and Takeda, outside of the submitted work. JB reports consulting fees for Merck Sharp and Dohme and Astra Zeneca, outside of the submitted work. APr reports personal honoraria from Pfizer, Roche, Merck Sharp and Dohme Oncology, Eli Lilly, and Daiichi Sankyo, outside of the submitted work; travel, accommodations, and expenses by Daiichi Sankyo, outside of the submitted work; research funding (to institution) from Roche and Novartis, outside of the submitted work; and consulting fees from NanoString Technologies, Amgen, Roche, Novartis, Pfizer, and Bristol-Myers Squibb, outside of the submitted work. APar reports consulting fees from Takeda and Novartis, outside of the submitted work. MT reports travel grants from Roche, Bristol-Myers Squibb, AstraZeneca, and Takeda, outside of the submitted work; and honoraria as a medical writer from Novartis and Amgen, outside the submitted work. AG reports consulting fees from Roche, Merck Sharp and Dohme, Eli Lilly, Pierre Fabre, Eisai, and Daichii Sankyo, outside the submitted work; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, AstraZeneca, Celgene, and Daichii Sankyo, outside the submitted work; research funds (to institution) from Eisai, Eli Lilly, and Roche, outside the submitted work; support for attending meetings or travel from Bristol-Myers Squibb, Merck Sharp and Dohme, Novartis, and Roche, outside the submitted work; and personal research funding from Associazione Italiana per la Ricerca sul Cancro Foundation UPO aging project, outside the submitted work. GG reports personal research funding outside of the submitted work from Associazione Italiana per la Ricerca sul Cancro Foundation, outside the submitted work; consulting fees from Janssen, Abbvie, AstraZeneca, and BeiGene, outside the submitted work; and speaker fees from Janssen and Abbvie, outside the submitted work. LR reports consulting fees from Servier, Amgen, ArQule, AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, Merck Sharp and Dohme, Nerviano Medical Sciences, Roche, Sanofi, and Zymeworks, outside the submitted work; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, and Sanofi, outside the submitted work; travel expenses from Ipsen, outside the submitted work; and institutional research funding (to institution) from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck Sharp and Dohme, Nerviano Medical Sciences, Roche, and Zymeworks, outside the submitted work. JT reports having a scientific consultancy role for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F Hoffmann-La Roche, Genentech, HalioDX, Hutchison MediPharma, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, Merck Sharp and Dohme, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics, and TheraMyc, outside of the submitted work; educational collaboration with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource, outside of the submitted work; and institutional financial interest in form of financial support for clinical trials or contracted research for Amgen, Array Biopharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International, F Hoffmann-La Roche, Genentech, HalioDX, Hutchison MediPharma International, Janssen-Cilag, MedImmune, Menarini, Merck Healt, Merck Sharp and Dohme, Merus, Mirati, Novartis Farmacéutica, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho, Spanish Association Against Cancer Scientific Foundation, and Cancer Research UK, outside the submitted work. ACo reports consulting fees from Merck Sharp and Dohme, Bristol Myers Squibb, AstraZeneca, and Roche, outside the submitted work; and speaker fees from AstraZeneca, Merck Sharp and Dohme, Novartis, and Astellas, outside the submitted work. All other authors declare no competing interests.

Figures

**Figure 2**
Prevalence of COVID-19 sequelae, hospital admissions due to COVID-19, and complicated COVID-19 across the six defined age categories Linear trends were tested with the Cochran–Armitage test. Numbers of patients are different across categories and age groups (appendix p 17).

**Figure 3**
Kaplan-Meier survival estimate of post-COVID-19 survival (days from post-COVID-19 reassessment to date of death or last follow-up) (A) Post-COVID-19 survival by presence of COVID-19 sequelae. (B) Post-COVID-19 survival by presence of COVID-19 respiratory or non-respiratory sequelae. (C) Post-COVID-19 survival by presence of one or two or more COVID-19 sequelae. (D) Post-COVID-19 survival by oncology therapeutic pathway. HR=hazard ratio. NR=not reached. SACT=systemic anticancer therapy.

See this image and copyright information in PMC

References

1. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–1926. - PMC - PubMed
1. Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed
1. Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–1316. - PMC - PubMed
1. Pinato DJ, Lee AJX, Biello F, et al. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe. Cancers (Basel) 2020;12 - PMC - PubMed
1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

30195/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Collaborators

Affiliations

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous